Weekend Sale Limited Time 65% Discount Offer - Ends in 0d 00h 00m 00s - Coupon code: ac4s65

Though it may not be required, TDM should still be used to confirm adequate dosing.

ASCP ASCP-MLT Full Course Access
ASCP ASCP-MLT View All Questions

Though it may not be required, TDM should still be used to confirm adequate dosing. Genotyping does not make TDM redundant.

A PM will metabolize the drug more slowly and therefore will need lower doses. CYP2D6 metabolizes many different drugs; it is not associated with just one class of drugs. Anytime a drug is taken that competes for the same metabolizing enzyme as another drug, there is potential for the concentrations of both drugs to be increased.

A patient has been characterized as a CYP2D6 poor metabolizer (PM) after genotyping. Which of the following statements is not true?

A.

The patient will likely need lower doses of CYP2D6-metabolized drugs.

B.

The patient is less likely to require therapeutic drug monitoring (TDM) since the genotype is known.

C.

CYP2D6 metabolizes many drugs, and so attention must be given to the doses of drugs from different classes.

ASCP-MLT PDF/Engine
  • Printable Format
  • Value of Money
  • 100% Pass Assurance
  • Verified Answers
  • Researched by Industry Experts
  • Based on Real Exams Scenarios
  • 100% Real Questions
buy now ASCP-MLT pdf
Get 65% Discount on All Products, Use Coupon: "ac4s65"
Next
In Rouleaux, red blood cells appear as stacked coins - formation occurs as the result...
All the following characteristics are accurate for the influence of Health Insurance Portability and Accountability...
Previous